trending Market Intelligence /marketintelligence/en/news-insights/trending/vjTUYrPtWGBSrvBAifQnuA2 content esgSubNav
In This List

Gilead to pay Kyverna $17.5M upfront in autoimmune disease partnership

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Gilead to pay Kyverna $17.5M upfront in autoimmune disease partnership

Gilead Sciences Inc. has signed a licensing agreement with Kyverna Therapeutics to develop T cell therapies to treat autoimmune diseases.

Kyverna will provide its synthetic T platform with a technology called synNotch, which was developed by Gilead's Kite Pharma unit.

Gilead will pay an upfront fee of $17.5 million, and Kyverna will be eligible for up to $570 million in development and commercialization milestones.

Kyverna will handle research and clinical studies, and Gilead will have an option to advance clinical development and commercialization efforts for any candidates that emerge from the partnership.